Short-term Clinical Effects of Intravitreal Aflibercept Injection 2.0mg as a Predictor of Long-term Results
Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
This is an open label study to evaluate 2.0 mg intravitreal aflibercept injection
administered in subject who have active choroidal neovascularization due to Age Related
Macular Degeneration (AMD).